Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an intravenous formulation for use in oncology. It is employed in the treatment of metastatic and advanced colorectal cancer and may be incorporated into combination regimens for other solid tumors.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Kabi is used in chemotherapy regimens targeting colorectal cancer and other solid tumors. - Metastatic colorectal cancer: improves progression‑free survival when combined with other agents. - Advanced colorectal cancer: used as part of first‑line or second‑line therapy to reduce tumor burden. - Other solid tumors (e.g., gastric, pancreatic): incorporated into combination protocols to enhance cytotoxic effect.

Irinotecan Kabi may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: may be managed with anti‑emetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: general tiredness affecting daily activities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Intestinal perforation: rare but life‑threatening bowel rupture. - Severe hypersensitivity reactions: including anaphylaxis, requiring immediate treatment.

When using Irinotecan Kabi, clinicians should observe several safety precautions to minimize risks. - Baseline blood counts: obtain CBC before each cycle to monitor neutropenia. - Liver function: assess hepatic enzymes as metabolism may be impaired. - Hydration: ensure adequate fluid intake to reduce risk of severe diarrhea. - Drug interactions: avoid concurrent strong CYP3A4 inhibitors that can increase SN‑38 exposure. - Pregnancy and lactation: contraindicated unless benefits outweigh unknown risks; discuss with specialist. - Store at ambient temperature: keep vials below 25 °C, protect from light, and retain in original packaging.

Irinotecan Kabi can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may raise SN‑38 levels, increasing toxicity. - UGT1A1 inhibitors (e.g., atazanavir): can reduce SN‑38 glucuronidation, heightening risk of neutropenia and diarrhea. - Concurrent use with other myelosuppressive agents: can exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as irinotecan may affect coagulation. - Antidiarrheal agents (e.g., loperamide): adjust dosing to avoid masking severe diarrhea. - Radiotherapy to abdomen/pelvis: increased gastrointestinal toxicity may occur.